Sandoz to Host Capital Markets Day: Maximising Sandoz Value in Its Golden Decade for Biosimilars

Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, announced it will host its 2026 capital markets day for investors and analysts on Tuesday, 8 September 2026, from 13:30 to 17:00 UK time at the London Stock Exchange. The event will be webcast live, with in-person attendance by invitation only on a first-come, first-served basis. This announcement comes as Sandoz positions itself to capitalize on what it calls the 'golden decade for biosimilars,' a period expected to bring significant growth opportunities as patents on major biologic drugs expire and healthcare systems seek cost-effective alternatives.

The capital markets day will provide insights into Sandoz's strategy to maximize shareholder value, focusing on its leadership in biosimilars and its broad portfolio of approximately 1,300 medicines. Sandoz, which traces its heritage back to 1886, recorded net sales of USD 11.1 billion in 2025. The company employs over 20,000 colleagues worldwide and reaches more than one billion patients, generating substantial global healthcare savings.

In addition to the capital markets day, Sandoz plans to host an investor and analyst site visit in Slovenia from 9-10 November, offering further insight into its new biosimilars development and supply-chain hub. This facility is central to Sandoz's growth plans, enhancing its ability to develop and manufacture biosimilars efficiently. Attendance will also be by invitation only and will not be webcast.

The capital markets day will be accessible via a live webcast, with details available here. The event is expected to cover key strategic initiatives, including pipeline updates, manufacturing capabilities, and financial targets. Sandoz emphasizes that its growth strategy is driven by its purpose: pioneering access for patients.

This announcement underscores the importance of biosimilars in the pharmaceutical industry. As biologic drugs lose patent protection, biosimilars offer a way to reduce healthcare costs while maintaining efficacy. Sandoz, a pioneer in the field, celebrates 20 years of biosimilars in 2026. The company's focus on this segment is timely, given the increasing demand for affordable biologics worldwide.

Forward-looking statements in the media release remind stakeholders that actual results may differ from expectations due to various risks and uncertainties, including global economic conditions, exchange rates, and competitive activities. Sandoz undertakes no obligation to publicly revise any forward-looking statements except as required by law.

For more information, the original release is available on NewMediaWire.